Brain serum amyloid P levels are reduced in individuals that lack Dementia while having Alzheimer's disease neuropathology

Neurochemical Research

Volumn 37, Issue 4, 2012, Pages 795-801

  Crawford, Jeffrey R ^a,b   Gomer, Richard H ^b   Bjorklund, Nicole L ^c   Taglialatela, Giulio ^c  

^a RICE UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Alzheimer's; Betaamyloid plaque; Hippocampus; Neurofibrillary tangle; Serum amyloid P

Indexed keywords

SERUM AMYLOID P;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUTOPSY; CLINICAL FEATURE; COGNITIVE DEFECT; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NON DEMENTED WITH ALZHEIMER DISEASE NEUROPATHOLOGY; PRIORITY JOURNAL; WOUND HEALING;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; SERUM AMYLOID P-COMPONENT;

EID: 84860198467     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-011-0674-0     Document Type: Article

References (39)

1. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362(4):329-344. doi:10.1056/NEJMra0909142
2. Guillozet AL, Weintraub S, Mash DC, Mesulam MM (2003) Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 60(5):729-736. doi:10.1001/archneur.60.5.729 (Pubitemid 36569891)
3. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66(12):1837-1844. doi:10.1212/01.wnl.0000219668.47116.e6 (Pubitemid 44049813)
4. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65(11):1509-1517. doi:10.1001/archneur.65.11.1509
5. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 106(16):6820-6825. doi:10.1073/pnas.0900345106
6. Pepys MB, Baltz ML (1983) Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 34:141-212 (Pubitemid 14089437)
7. Thompson D, Pepys MB, Tickle I, Wood S (2002) The structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactose. J Mol Biol 320(5):1081-1086 (Pubitemid 34808825)
8. Yasojima K, Schwab C, McGeer EG, McGeer PL (2000) Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 887(1):80-89 (Pubitemid 32008026)
9. Kimura M, Asada T, Uno M, Machida N, Kasuya K, Taniguchi Y, Fujita T, Nishiyama E, Iwamoto N, Arai H (1999) Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease. Neurosci Lett 273(2):137-139 (Pubitemid 29428126)
10. Mulder C, Schoonenboom SN, Wahlund LO, Scheltens P, van Kamp GJ, Veerhuis R, Hack CE, Blomberg M, Schutgens RB, Eikelenboom P (2002) CSF markers related to pathogenetic mechanisms in Alzheimer's disease. J Neural Transm 109(12): 1491-1498. doi:10.1007/s00702-002-0763-y (Pubitemid 36057058)
11. Verwey NA, Schuitemaker A, van der Flier WM, Mulder SD, Mulder C, Hack CE, Scheltens P, Blankenstein MA, Veerhuis Rb(2008) Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 26(6):522-527. doi:10.1159/000178756
12. Emsley J, White HE, O'Hara BP, Oliva G, Srinivasan N, Tickle IJ, Blundell TL, Pepys MB, Wood SP (1994) Structure of pen- tameric human serum amyloid P component. Nature 367(6461): 338-345. doi:10.1038/367338a0 (Pubitemid 24062339)
13. Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E (1997) Amyloid P component. A critical review. Amyloid 4:274-295
14. Naik-Mathuria B, Pilling D, Crawford JR, Gay AN, Smith CW, Gomer RH, Olutoye OO (2008) Serum amyloid P inhibits dermal wound healing. Wound Repair Regen 16(2):266-273. doi: 10.1111/j.1524-475X.2008.00366.x (Pubitemid 351342135)
15. Agrawal A, Singh PP, Bottazzi B, Garlanda C, Mantovani A (2009) Pattern recognition by pentraxins. Adv Exp Med Biol 653: 98-116
16. Gomer RH, Pilling D, Kauvar LM, Ellsworth S, Ronkainen SD, Roife D, Davis SC (2009) A serum amyloid P-binding hydrogel speeds healing of partial thickness wounds in pigs. Wound Repair Regen 17(3):397-404. doi:10.1111/j.1524- 475X.2009.00482.x
17. Pilling D, Roife D, Wang M, Ronkainen SD, Crawford JR, Travis EL, Gomer RH (2007) Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol 179(6): 4035-4044. doi:179/6/4035[pii]
18. Castano AP, Lin SL, Surowy T, Nowlin BT, Turlapati SA, Patel T, Singh A, Li S, Lupher ML, Jr., Duffield JS (2009) Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 1 (5):5ra13. doi:10.1126/scitranslmed.3000111
19. Moreira AP, Cavassani KA, Hullinger R, Rosada RS, Fong DJ, Murray L, Hesson DP, Hogaboam CM (2010) Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. J Allerg Clin Immunol 126(4):712-721. doi:10.1016/j.jaci.2010.06.010e717
20. Murray LA, Chen Q, Kramer MS, Hesson DP, Argentieri RL, Peng X, Gulati M, Homer RJ, Russell T, van Rooijen N, Elias JA, Hogaboam CM, Herzog EL (2011) TGF-beta driven lung fibrosis is macrophage dependent and blocked by serum amyloid P. Int J Biochem Cell Biol 43(1):154-162. doi:10.1016/j.biocel.2010.10. 013
21. Murray LA, Kramer MS, Hesson DP, Watkins BA, Fey EG, Argentieri RL, Shaheen F, Knight DA, Sonis ST (2010) Serum amyloid P ameliorates radiation-induced oral mucositis and fibrosis. Fibrogenesis Tissue Repair3:11. doi:10.1186/1755-1536-3-11
22. Coria F, Castano E, Prelli F, Larrondo-Lillo M, van Duinen S, Shelanski ML, Frangione B (1988) Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab Invest 58(4):454-458
23. Kalaria RN, Grahovac I (1990) Serum amyloid P immunoreac- tivity in hippocampal tangles, plaques and vessels: implications for leakage across the blood-brain barrier in Alzheimer's disease. Brain Res 516(2):349-353 (Pubitemid 20185568)
24. McGeer EG, Yasojima K, Schwab C, McGeer PL (2001) The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases. Neurobiol Aging 22(6):843-848 (Pubitemid 34066551)
25. Urbanyi Z, Laszlo L, Tomasi TB, Toth E, Mekes E, Sass M, Pazmany T (2003) Serum amyloid P component induces neuronal apoptosis and beta-amyloid immunoreactivity. Brain Res 988(1-2):69-77 (Pubitemid 37289495)
26. Urbanyi Z, Sass M, Laszy J, Takacs V, Gyertyan I, Pazmany T (2007) Serum amyloid P component induces TUNEL-positive nuclei in rat brain after intrahippocampal administration. Brain Res 1145:221-226. doi:10.1016/j.brainres. 2007.01.132 (Pubitemid 46497989)
27. Tennent GA, Lovat LB, Pepys MB (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 92(10):4299-4303
28. Janciauskiene S, Garcia de Frutos P, Carlemalm E, Dahlback B, Eriksson S (1995) Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component. J Biol Chem 270(44): 26041-26044 (Pubitemid 3006164)
29. Pepys MB (2006) Amyloidosis. Annu Rev Med 57:223-241. doi: 10.1146/annurev.med.57.121304.131243 (Pubitemid 43261989)
30. Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, Pepys MB (1997) Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 3(8):855-859 (Pubitemid 27353444)
31. Togashi S, Lim SK, Kawano H, Ito S, Ishihara T, Okada Y, Nakano S, Kinoshita T, Horie K, Episkopou V, Gottesman ME, Costantini F, Shimada K, Maeda S (1997) Serum amyloid P component enhances induction of murine amyloidosis. Lab Invest 77(5):525-531 (Pubitemid 27508623)
32. Pilling D, Buckley CD, Salmon M, Gomer RH (2003) Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 17(10):5537-5546 (Pubitemid 37432844)
33. Romijn HJ, van Uum JF, Breedijk I, Emmering J, Radu I, Pool CW (1999) Double immunolabeling of neuropeptides in the human hypothalamus as analyzed by confocal laser scanning fluorescence microscopy. J Histochem Cytochem 47(2):229-236
34. Edelstein A, Amodaj N, Hoover K, Vale R, Stuurman N (2010) Computer control of microscopes using microManager. Curr Protoc Mol Biol Chapter 14:Unit14 20. doi:10.1002/0471142727.mb1420s92
35. Duong T, Pommier EC, Scheibel AB (1989) Immunodetection of the amyloid P component in Alzheimer's disease. Acta Neuro- pathol 78(4):429-437 (Pubitemid 19200593)
36. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT (2010) Inflammation and Alzheimer's disease. Arch Pharm Res 33(10): 1539-1556. doi:10.1007/s12272-010- 1006-7
37. ouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH (1994) Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex 4(2):138-150 (Pubitemid 24127824)
38. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417(6886):254-259 (Pubitemid 34534701)
39. Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB (2009) Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci USA 106(18): 7619-7623. doi:10.1073/pnas.0902640106